ADX-096
Complement-Mediated Diseases
PreclinicalActive; Strategic options being evaluated
Key Facts
Indication
Complement-Mediated Diseases
Phase
Preclinical
Status
Active; Strategic options being evaluated
Company
About Q32 Bio
Q32 Bio's mission is to transform patient lives by rebalancing the immune system through targeted modulation of innate and adaptive immune pathways. The company has achieved Fast Track designation for its lead candidate, bempikibart, in alopecia areata and is advancing a Phase 2a trial. Its strategy leverages a dual-pronged approach: advancing its adaptive immune modulator in high-need autoimmune indications and developing a next-generation platform for tissue-targeted complement inhibition.
View full company profileTherapeutic Areas
Other Complement-Mediated Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| mHam 2.0 – Complement-Dependent Cell Killing Assay | Machaon Diagnostics | Commercial |
| ANX1502 | Annexon | Phase 1 |
| C3d mAb fusions & nanobodies | Q32 Bio | Discovery |
| RLYB116 | Rallybio | Phase 1 |